COVID-19: Indian Vaccine ‘COVAXIN’ Gets Permission For Human Clinical Trials
India’s first indigenous Coronavirus vaccine COVAXIN, developed by Bharat Biotech International, has been given the nod by Drug Controller General of India.
Amongst the plentiful efforts around the world to come up with a vaccine to combat the spread of COVID-19 is India’s very own COVAXIN, which has just been given the nod for conducting human trials by the Drug Controller General of India (DCGI). The permission for these human clinical trials was given by the DCGI following the analysis of preclinical studies that demonstrated safety and immune response. This nod allows India’s efforts to deliver a COVID-19 vaccine to cross a major milestone. COVAXIN is India’s first indigenous potential vaccine against Coronavirus.
It is being developed by Bharat Biotech International (BBI), in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology. The human trials of COVAXIN, which are now scheduled to begin across India in the month of July, will take place in two phases. If they turn out to be successful, it will mark a major breakthrough in the fight against the deadly coronavirus, which has already taken more than 16,000 lives in India.
Get more news updates on ZEE5.